Phase 1
Completed N=22
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Source: ClinicalTrials.gov NCT03307785 ↗Enrolled (actual)
22
Serious AEs
59.0%
Results posted
May 2021
Primary outcomePrimary: Part A: Number of Participants With Dose-limiting Toxicity (DLT) — 2; 0 Participants
Summary
Part A: To test the safety and tolerability of combination therapy with Niraparib and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.
Part B: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.
Part C: To test the safety and tolerability of combination therapy with Niraparib, TSR-042 and Bevacizumab and to establish a safe dose that will be used in a Phase 2 study.
Part D: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel, TSR-042 and Bevacizumab and to establish a safe dose that will be used in a Phase 2 study.
Part E: To test the safety and tolerability of combination therapy with Carboplatin-Pemetrexed and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.
Part F: To test the safety and tolerability of combination therapy with Carboplatin-Pemetrexed, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.
Part G: To test the safety and tolerability of combination therapy with Carboplatin-nab-Paclitaxel, TSR-042 and to establish a safe dose that will be used in a Phase 2 study.
Part H: To test the safety and tolerability of combination therapy with Carboplatin-nab-Paclitaxel, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.
Part I: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Part A: Number of Participants With Dose-limiting Toxicity (DLT) |
2; 0 | — |
| PRIMARY Part B: Number of Participants With DLT |
1 | — |
| PRIMARY Part C: Number of Participants With DLT |
1; 1 | — |
| PRIMARY Part D: Number of Participants With DLT |
— | — |
| PRIMARY Part E: Number of Participants With DLT |
— | — |
| PRIMARY Part F: Number of Participants With DLT |
— | — |
| PRIMARY Part G: Number of Participants With DLT |
— | — |
| PRIMARY Part H: Number of Participants With DLT |
— | — |
| PRIMARY Part I: Number of Participants With DLT |
— | — |
| PRIMARY Part A: Number of Participants With Non-serious Treatment-emergent Adverse Events (TEAEs), Serious TEAEs (STEAEs) and Adverse Events of Special Interest (AESIs) |
16; 6; 11; 4; 1; 1 | — |
| PRIMARY Part B: Number of Participants With Non-serious TEAEs, STEAEs and AESIs |
14; 9; 0 | — |
| PRIMARY Part C: Number of Participants With Non-serious TEAEs, STEAEs and AESIs |
5; 7; 3; 3; 0; 0 | — |
| PRIMARY Part D: Number of Participants With Non-serious TEAEs, STEAEs and AESIs |
6; 3; 0 | — |
| PRIMARY Part E: Number of Participants With Non-serious TEAEs, STEAEs and AESIs |
2; 2; 0 | — |
| PRIMARY Part F: Number of Participants With Non-serious TEAEs, STEAEs and AESIs |
1; 0; 0 | — |
| PRIMARY Part G: Number of Participants With Non-serious TEAEs, STEAEs and AESIs |
— | — |
| PRIMARY Part H: Number of Participants With Non-serious TEAEs, STEAEs and AESIs |
— | — |
| PRIMARY Part I: Number of Participants With Non-serious TEAEs, STEAEs and AESIs |
— | — |
| SECONDARY Part A: Objective Response Rate |
25.0; 0 | — |
| SECONDARY Part B: Objective Response Rate |
42.9 | — |
| SECONDARY Part C: Objective Response Rate |
50.0; 14.3 | — |
| SECONDARY Part D: Objective Response Rate |
50.0 | — |
| SECONDARY Part E: Objective Response Rate |
— | — |
| SECONDARY Part F: Objective Response Rate |
— | — |
| SECONDARY Part G: Objective Response Rate |
— | — |
| SECONDARY Part H: Objective Response Rate |
— | — |
| SECONDARY Part I: Objective Response Rate |
— | — |
| SECONDARY Part A: Duration of Response |
7.59; NA | — |
| SECONDARY Part B: Duration of Response |
NA | — |
| SECONDARY Part C: Duration of Response |
NA; NA | — |
| SECONDARY Part D: Duration of Response |
NA | — |
| SECONDARY Part E: Duration of Response |
NA | — |
| SECONDARY Part F: Duration of Response |
NA | — |
| SECONDARY Part G: Duration of Response |
— | — |
| SECONDARY Part H: Duration of Response |
— | — |
| SECONDARY Part I: Duration of Response |
— | — |
| SECONDARY Part A: Disease Control Rate |
43.8; 33.3 | — |
| SECONDARY Part B: Disease Control Rate |
57.1 | — |
| SECONDARY Part C: Disease Control Rate |
83.3; 85.7 | — |
| SECONDARY Part D: Disease Control Rate |
83.3 | — |
| SECONDARY Part E: Disease Control Rate |
— | — |
| SECONDARY Part F: Disease Control Rate |
100 | — |
| SECONDARY Part G: Disease Control Rate |
— | — |
| SECONDARY Part H: Disease Control Rate |
— | — |
| SECONDARY Part I: Disease Control Rate |
— | — |
| SECONDARY Part A: Progression-free Survival |
6.2; 2.8 | — |
| SECONDARY Part B: Progression-free Survival |
17.6 | — |
| SECONDARY Part C: Progression-free Survival |
NA; 9.1 | — |
| SECONDARY Part D: Progression-free Survival |
7.6 | — |
| SECONDARY Part E: Progression-free Survival |
NA | — |
| SECONDARY Part F: Progression-free Survival |
NA | — |
| SECONDARY Part G: Progression-free Survival |
— | — |
| SECONDARY Part H: Progression-free Survival |
— | — |
| SECONDARY Part I: Progression-free Survival |
— | — |
| SECONDARY Part A: Number of Participants With Positive Anti-TSR-042 Antibodies |
0; 0 | — |
| SECONDARY Part B: Number of Participants With Positive Anti-TSR-042 Antibodies |
4 | — |
| SECONDARY Part C: Number of Participants With Positive Anti-TSR-042 Antibodies |
0; 0 | — |
| SECONDARY Part D: Number of Participants With Positive Anti-TSR-042 Antibodies |
— | — |
| SECONDARY Part E: Number of Participants With Positive Anti-TSR-042 Antibodies |
— | — |
| SECONDARY Part F: Number of Participants With Positive Anti-TSR-042 Antibodies |
NA | — |
| SECONDARY Part F: Number of Participants With Positive Anti-TSR-022 Antibodies |
NA | — |
| SECONDARY Part G: Number of Participants With Positive Anti-TSR-042 Antibodies |
— | — |
| SECONDARY Part H: Number of Participants With Positive Anti-TSR-042 Antibodies |
— | — |
| SECONDARY Part H: Number of Participants With Positive Anti-TSR-022 Antibodies |
— | — |
| SECONDARY Part I: Number of Participants With Positive Anti-TSR-042 Antibodies |
— | — |
| SECONDARY Part I: Number of Participants With Positive Anti-TSR-022 Antibodies |
— | — |
| SECONDARY Part A: Area Under the Plasma Concentration From Time Zero to t (AUC[0-t]) of Niraparib |
6.0430; 7.8341; 14.9172; 29.3024 | — |
| SECONDARY Part A: AUC(0-t) of TSR-042 |
26827.7703; 29420.8347; 55408.3992; 29311.8182; 137108.2574; 141328.9288 | — |
| SECONDARY Part B: AUC0-t of TSR-042 |
28097.9846; 54730.0053; 124309.5455; 117030.4081 | — |
| SECONDARY Part C: AUC0-t of Niraparib |
3.4513; 11.3601; 14.7473; 24.9691 | — |
| SECONDARY Part C: AUC0-t of TSR-042 |
29830.6542; 26311.1789; 54268.1379; 49198.8237; 137777.3188; 131281.9046 | — |
| SECONDARY Part D: AUC0-t of TSR-042 |
32819.5401; 52409.0255; 119847.0999; 77794.6422 | — |
| SECONDARY Part E: AUC0-t of TSR-042 |
NA | — |
| SECONDARY Part F: AUC0-t of TSR-042 |
NA | — |
| SECONDARY Part F: AUC0-t of TSR-022 |
NA | — |
| SECONDARY Part G: AUC0-t of TSR-042 |
— | — |
| SECONDARY Part H: AUC0-t of TSR-042 |
— | — |
| SECONDARY Part H: AUC0-t of TSR-022 |
— | — |
| SECONDARY Part I: AUC0-t of TSR-042 |
— | — |
| SECONDARY Part I: AUC0-t of TSR-022 |
— | — |
| SECONDARY Part A: Area Under the Plasma Concentration From Time Zero to Infinity (AUC[0-infinity]) of Niraparib |
NA; NA | — |
| SECONDARY Part A: AUC(0-infinity) of TSR-042 |
NA; NA | — |
| SECONDARY Part B: AUC(0-infinity) of TSR-042 |
NA | — |
| SECONDARY Part C: AUC(0-infinity) of Niraparib |
NA; NA | — |
| SECONDARY Part C: AUC(0-infinity) of TSR-042 |
NA; NA | — |
| SECONDARY Part D: AUC(0-infinity) of TSR-042 |
NA | — |
| SECONDARY Part E: AUC(0-infinity) of TSR-042 |
NA | — |
| SECONDARY Part F: AUC(0-infinity) of TSR-042 |
NA | — |
| SECONDARY Part F: AUC(0-infinity) of TSR-022 |
NA | — |
| SECONDARY Part G: AUC(0-infinity) of TSR-042 |
— | — |
| SECONDARY Part H: AUC(0-infinity) of TSR-042 |
— | — |
| SECONDARY Part H: AUC(0-infinity) of TSR-022 |
— | — |
| SECONDARY Part I: AUC(0-infinity) of TSR-042 |
— | — |
| SECONDARY Part I: AUC(0-infinity) of TSR-022 |
— | — |
| SECONDARY Part A: Observed Concentration at the End of the Dosing Interval (Ctau) of Niraparib |
0.191953; 0.342333 | — |
| SECONDARY Part A: Ctau of TSR-042 |
33.6000; 29.8000 | — |
| SECONDARY Part B: Ctau of TSR-042 |
33.9778 | — |
| SECONDARY Part C: Ctau of Niraparib |
0.161233; 0.478714 | — |
| SECONDARY Part C: Ctau of TSR-042 |
37.2750; 28.7500 | — |
| SECONDARY Part D: Ctau of TSR-042 |
36.5250 | — |
| SECONDARY Part E: Ctau of TSR-042 |
NA | — |
| SECONDARY Part F: Ctau of TSR-042 |
NA | — |
| SECONDARY Part F: Ctau of TSR-022 |
NA | — |
| SECONDARY Part G: Ctau of TSR-042 |
— | — |
| SECONDARY Part H: Ctau of TSR-042 |
— | — |
| SECONDARY Part H: Ctau of TSR-022 |
— | — |
| SECONDARY Part I: Ctau of TSR-042 |
— | — |
| SECONDARY Part I: Ctau of TSR-022 |
— | — |
| SECONDARY Part A: Maximum Observed Plasma (Cmax) of Niraparib |
0.460600; 0.625667 | — |
| SECONDARY Part A: Cmax of TSR-042 |
158.6875; 138.9167 | — |
| SECONDARY Part B: Cmax of TSR-042 |
148.2000 | — |
| SECONDARY Part C: Cmax of Niraparib |
0.243667; 0.891571 | — |
| SECONDARY Part C: Cmax of TSR-042 |
138.6667; 158.4857 | — |
| SECONDARY Part D: Cmax of TSR-042 |
188.5000 | — |
| SECONDARY Part E: Cmax of TSR-042 |
NA | — |
| SECONDARY Part F: Cmax of TSR-042 |
NA | — |
| SECONDARY Part F: Cmax of TSR-022 |
NA | — |
| SECONDARY Part G: Cmax of TSR-042 |
— | — |
| SECONDARY Part H: Cmax of TSR-042 |
— | — |
| SECONDARY Part H: Cmax of TSR-022 |
— | — |
| SECONDARY Part I: Cmax of TSR-042 |
— | — |
| SECONDARY Part I: Cmax of TSR-022 |
— | — |
| SECONDARY Part A: Clearance After Oral Administration (CL/F) of Niraparib |
28.5638; 16.6295; 10.2833 | — |
| SECONDARY Part A: Clearance After Intravenous Administration (CL) of TSR-042 |
0.0090; 0.0110; 0.0081; 0.0071; 0.0072 | — |
| SECONDARY Part B: CL of TSR-042 |
0.0098; 0.0082; 0.0092 | — |
| SECONDARY Part C: CL/F of Niraparib |
10.3777; 14.4947 | — |
| SECONDARY Part C: CL of TSR-042 |
0.0100; 0.0104; 0.0082; 0.0082; 0.0079; 0.0086 | — |
| SECONDARY Part D: CL of TSR-042 |
0.0102; 0.0087; 0.0104 | — |
| SECONDARY Part E: CL of TSR-042 |
NA | — |
| SECONDARY Part F: CL of TSR-042 |
NA | — |
| SECONDARY Part F: CL of TSR-022 |
NA | — |
| SECONDARY Part G: CL of TSR-042 |
— | — |
| SECONDARY Part H: CL of TSR-042 |
— | — |
| SECONDARY Part H: CL of TSR-022 |
— | — |
| SECONDARY Part I: CL of TSR-042 |
— | — |
| SECONDARY Part I: CL of TSR-022 |
— | — |
| SECONDARY Part A: Volume of Distribution After Oral Administration (Vz/F) of Niraparib |
380.1478; 716.1418; 487.8826 | — |
| SECONDARY Part A: Volume of Distribution After Intravenous Administration (Vz) of of TSR-042 |
5.6925; 10.3984; 6.8811; 6.3070; 7.4795 | — |
| SECONDARY Part B: Vz of TSR-042 |
5.3661; 7.2627; 8.0529 | — |
| SECONDARY Part C: Vz/F of Niraparib |
551.4003; 559.3634 | — |
| SECONDARY Part C: Vz of TSR-042 |
6.6462; 5.8922; 6.1698; 5.2066; 9.6347; 8.5098 | — |
| SECONDARY Part D: Vz of TSR-042 |
5.4955; 6.1542; 9.8356 | — |
| SECONDARY Part E: Vz of TSR-042 |
NA | — |
| SECONDARY Part F: Vz of TSR-042 |
NA | — |
| SECONDARY Part F: Vz of TSR-022 |
NA | — |
| SECONDARY Part G: Vz of TSR-042 |
— | — |
| SECONDARY Part H: Vz of TSR-042 |
— | — |
| SECONDARY Part H: Vz of TSR-022 |
— | — |
| SECONDARY Part I: Vz of TSR-042 |
— | — |
| SECONDARY Part I: Vz of TSR-022 |
— | — |
| SECONDARY Part A: AUC at Steady State (AUCss) of Niraparib |
16.3481; 29.4312 | — |
| SECONDARY Part A: AUCss of TSR-042 |
58598.5076; 46122.3924; 135171.2753; 141306.3782; 151575.3645 | — |
| SECONDARY Part B: AUCss of TSR-042 |
55073.0926; 130694.9752; 117033.3612 | — |
| SECONDARY Part C: AUCss of Niraparib |
21.4926; 26.5006 | — |
| SECONDARY Part C: AUCss of TSR-042 |
55974.4268; 50924.1510; 137399.5881; 131288.0291; 147907.5379; 119189.5905 | — |
| SECONDARY Part D: AUCss of TSR-042 |
51140.4410; 118845.3928; 96800.1534 | — |
| SECONDARY Part E: AUCss of TSR-042 |
NA | — |
| SECONDARY Part F: AUCss of TSR-042 |
NA | — |
| SECONDARY Part F: AUCss of TSR-022 |
NA | — |
| SECONDARY Part G: AUCss of TSR-042 |
— | — |
| SECONDARY Part H: AUCss of TSR-042 |
— | — |
| SECONDARY Part H: AUCss of TSR-022 |
— | — |
| SECONDARY Part I: AUCss of TSR-042 |
— | — |
| SECONDARY Part I: AUCss of TSR-022 |
— | — |
| SECONDARY Part A: Ctau at Steady State (Ctau,ss) of Niraparib |
0.507900; 0.622000 | — |
| SECONDARY Part A: Ctau,ss of TSR-042 |
77.3625; 63.3000; 68.5500; 71.2000; 93.8000 | — |
| SECONDARY Part B: Ctau,ss of TSR-042 |
67.2444; 59.3000; 57.4833 | — |
| SECONDARY Part C: Ctau,ss of Niraparib |
0.484000; 1.094250 | — |
| SECONDARY Part C: Ctau,ss of TSR-042 |
70.4250; 64.2667; 82.9800; 53.1500; 105.4667; 60.9500 | — |
| SECONDARY Part D: Ctau,ss of TSR-042 |
53.5200; 48.0800; 43.3000 | — |
| SECONDARY Part E: Ctau,ss of TSR-042 |
NA | — |
| SECONDARY Part F: Ctau,ss of TSR-042 |
NA | — |
| SECONDARY Part F: Ctau,ss of TSR-022 |
NA | — |
| SECONDARY Part G: Ctau,ss of TSR-042 |
— | — |
| SECONDARY Part H: Ctau,ss of TSR-042 |
— | — |
| SECONDARY Part H: Ctau,ss of TSR-022 |
— | — |
| SECONDARY Part I: Ctau,ss of TSR-042 |
— | — |
| SECONDARY Part I: Ctau,ss of TSR-022 |
— | — |
| SECONDARY Part A: Cmax at Steady State (Cmax,ss) of Niraparib |
0.925900; 1.706667; 0.839071; 0.768000 | — |
| SECONDARY Part A: Cmax,ss of TSR-042 |
222.5556; 178.5000; 393.8750; 319.0000; 405.4000 | — |
| SECONDARY Part B: Cmax,ss of TSR-042 |
225.8000; 421.1111; 446.6667 | — |
| SECONDARY Part C: Cmax,ss of Niraparib |
0.854500; 1.404750; 0.709750; 1.073667; 0.468333; 0.638000 | — |
| SECONDARY Part C: Cmax,ss of TSR-042 |
234.4000; 227.1429; 325.2000; 417.3333; 349.7500; 321.0000 | — |
| SECONDARY Part D: Cmax,ss of TSR-042 |
256.8000; 416.0000; 429.7500 | — |
| SECONDARY Part E: Cmax,ss of TSR-042 |
NA | — |
| SECONDARY Part F: Cmax,ss of TSR-042 |
NA | — |
| SECONDARY Part F: Cmax,ss of TSR-022 |
NA | — |
| SECONDARY Part G: Cmax,ss of TSR-042 |
— | — |
| SECONDARY Part H: Cmax,ss of TSR-042 |
— | — |
| SECONDARY Part H: Cmax,ss of TSR-022 |
— | — |
| SECONDARY Part I: Cmax,ss of TSR-042 |
— | — |
| SECONDARY Part I: Cmax,ss of TSR-022 |
— | — |
| SECONDARY Part A: Time to Reach Maximum Plasma Concentration (Tmax) of Niraparib |
2.250; 4.083 | — |
| SECONDARY Part A: Tmax of TSR-042 |
0.817; 1.750 | — |
| SECONDARY Part B: Tmax of TSR-042 |
1.000 | — |
| SECONDARY Part C: Tmax of Niraparib |
3.975; 4.050 | — |
| SECONDARY Part C: Tmax of TSR-042 |
1.200; 0.583 | — |
| SECONDARY Part D: Tmax of TSR-042 |
1.250 | — |
| SECONDARY Part E: Tmax of TSR-042 |
NA | — |
| SECONDARY Part F: Tmax of TSR-042 |
NA | — |
| SECONDARY Part F: Tmax of TSR-022 |
NA | — |
| SECONDARY Part G: Tmax of TSR-042 |
— | — |
| SECONDARY Part H: Tmax of TSR-042 |
— | — |
| SECONDARY Part H: Tmax of TSR-022 |
— | — |
| SECONDARY Part I: Tmax of TSR-042 |
— | — |
| SECONDARY Part I: Tmax of TSR-022 |
— | — |
| SECONDARY Part A: Tmax at Steady State (Tmax,ss) of Niraparib |
4.008; 2.250; 2.000; 1.817 | — |
| SECONDARY Part A: Tmax,ss of TSR-042 |
1.500; 1.300; 0.625; 2.783; 0.567 | — |
| SECONDARY Part B: Tmax,ss of TSR-042 |
0.575; 1.500; 0.542 | — |
| SECONDARY Part C: Tmax,ss of Niraparib |
4.950; 3.958; 2.158; 1.967; 2.000; 2.083 | — |
| SECONDARY Part C: Tmax,ss of TSR-042 |
1.517; 0.617; 2.083; 0.825; 2.000; 2.417 | — |
| SECONDARY Part D: Tmax,ss of TSR-042 |
0.500; 0.550; 0.500 | — |
| SECONDARY Part E: Tmax,ss of TSR-042 |
NA | — |
| SECONDARY Part F: Tmax,ss of TSR-042 |
NA | — |
| SECONDARY Part F: Tmax,ss of TSR-022 |
NA | — |
| SECONDARY Part G: Tmax,ss of TSR-042 |
— | — |
| SECONDARY Part H: Tmax,ss of TSR-042 |
— | — |
| SECONDARY Part H: Tmax,ss of TSR-022 |
— | — |
| SECONDARY Part I: Tmax,ss of TSR-042 |
— | — |
| SECONDARY Part I: Tmax,ss of TSR-022 |
— | — |
| SECONDARY Part A: Volume of Distribution After Intravenous Administration (Vss) of of TSR-042 |
5.5647; 9.8680; 6.6580; 5.9659; 7.3107 | — |
| SECONDARY Part B: Vss of TSR-042 |
5.1893; 6.7701; 7.4351 | — |
| SECONDARY Part C: Vss of TSR-042 |
6.4567; 5.5177; 6.2405; 4.8035; 8.9478; 7.7750 | — |
| SECONDARY Part D: Vss of TSR-042 |
5.1493; 5.6399; 8.0614 | — |
| SECONDARY Part E: Vss of TSR-042 |
NA | — |
| SECONDARY Part F: Vss of TSR-042 |
NA | — |
| SECONDARY Part F: Vss of TSR-022 |
NA | — |
| SECONDARY Part G: Vss of TSR-042 |
— | — |
| SECONDARY Part H: Vss of TSR-042 |
— | — |
| SECONDARY Part H: Vss of TSR-022 |
— | — |
| SECONDARY Part I: Vss of TSR-042 |
— | — |
| SECONDARY Part I: Vss of TSR-022 |
— | — |
Eligibility Criteria
Inclusion Criteria
- Patient has histologically or cytologically proven advanced (unresectable) or metastatic cancer as outlined below according to study part and disease type:
- Part A: Patients with previously treated advanced or metastatic cancer. Patient may have received no more than 4 lines of treatment for advanced or metastatic cancer. Hormonal treatment will not be considered a prior line of treatment.
- Part B: Patients with advanced or metastatic cancer for which treatment with carboplatin-paclitaxel is considered appropriate therapy. Patient may have received no more than 1 prior line of chemotherapy in the metastatic setting. Hormonal treatment will not be considered a prior line of treatment.
- Part C: Patients with previously treated advanced or metastatic cancer. Patient may have received no more than 4 lines of treatment for advanced or metastatic cancer. Hormonal treatment will not be considered a prior line of treatment.
- Part D: Patients in whom carboplatin-paclitaxel and bevacizumab is considered appropriate therapy. Patient may have received no more than 1 prior line of chemotherapy in the metastatic setting. Hormonal treatment will not be considered a prior line of treatment.
- Part E and F: Patients who have not received prior systemic therapy, including targeted therapy and biologic agents, for their advanced or metastatic (Stage ≥ IIIB or IV) Non-Squamous NSCLC. Patients who have received neoadjuvant or adjuvant therapy are eligible as long as development of advanced or metastatic disease occurred at least 12 months after completion of neoadjuvant or adjuvant therapy.
- Part G, H, and I: Patients who have not received prior systemic therapy, including targeted therapy and biologic agents, for their advanced or metastatic (Stage ≥ IIIB or IV) NSCLC. Patients who have received neoadjuvant or adjuvant therapy are eligible as long as development of advanced or metastatic disease occurred at least 12 months after completion of neoadjuvant or adjuvant therapy.
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- Patient has adequate organ function.
- Female patient has a negative serum pregnancy test within 72 hours prior to taking study treatment if of childbearing potential and agrees to abstain from activities that could result in pregnancy from screening through 180 days after the last dose of study treatment, or is of non-childbearing potential.
- Male patient agrees to use an adequate method of contraception and not donate sperm starting with the first dose of study treatment through 90 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.
- Patient has measurable lesions by RECIST v1.1.
For Part A and C, in addition to the general inclusion criteria, patients must also meet the following additional criterion to be considered eligible to participate in this study:
- Patient is able to take oral medications.
- For patients to be eligible for any parts of the study using niraparib 300 mg as a starting dose, a screening actual body weight ≥ 77 kg and screening platelet count ≥ 150,000 u/L is necessary.
Exclusion Criteria: (Patients will not be eligible for the study entry if any of the following criteria are met)
- Patient has known active central nervous system metastases, carcinomatous meningitis, or both.
- Patient has a known additional malignancy that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.
- Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active infection that requires systemic therapy.
- Patient has a condition (such as transfusion-dependent anemia or thrombocytopenia), therapy, or laboratory abnor
Data sourced from ClinicalTrials.gov (NCT03307785). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.